Imunon says Phase 3 ovarian cancer trial enrollment ahead of schedule

July 30, 2026 9:00 AM

Imunon, Inc. (Nasdaq: IMNN) reported that enrollment in its pivotal Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found